We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Prevails In Battle for Biovail's Generic Wellbutrin Tablets
Teva Prevails In Battle for Biovail's Generic Wellbutrin Tablets
March 20, 2007
Sales of buproprion hydrochloride extended-release are expected to continue for two more months, according a new agreement aimed at resolving patent litigation brought by Biovail to block generic versions of its antidepressant drug, Wellbutrin XL.